Table 3. Patient characteristics.
| Gleason score | Number of patients | |||
|---|---|---|---|---|
| 6 | 9 (9%) | |||
| 7 | 21 (21%) | |||
| 8 | 24 (24%) | |||
| 9 | 31 (31%) | |||
| 10 | 6 (6%) | |||
| unknown | 9 (9%) | |||
| Prior and ongoing therapies | ||||
| Therapy | History: n (%) | Ongoing: n (%) | ||
| Prostatectomy | 52 (52%) | |||
| Abiraterone | 51 (51%) | 21 (21%) | ||
| Enzalutamide | 33 (33%) | 39 (39%) | ||
| Chemotherapy* | 70 (70 %) | |||
| Bisphosphonate or RANKL+ inhibitor | 12 (12%) | 69 (69%) | ||
| Ra-223 | 36 (36 %) | |||
| Regular need for analgesics! | 39 (39 %) | |||
| Extent of disease in 100 patients, detected by 68Ga-PSMA-PET/CT | ||||
| Number of patients (%) | Extent | |||
| Local recurrence | 40 (40%) | |||
| Bone metastases | 98 (98 %) | < 20 metastases in 29 patients (29.6%) > 20 metastases in 45 patients (45.9%) diffuse metastases in 24 patients (24.5%) |
||
| Lymph node metastases | 78 (78 %) | iliac and abdominal in 33 patients (42.3%) thoracic in 9 patients (11.5%) iliac to thoracic in 36 patients (46.2%) |
||
| Liver metastases | 13 (13%) | singular metastasis in 1 patient multiple metastases in 12 patients |
||
| Lung metastases | 15 (15%) | singular metastasis in 2 patients multiple metastases in 13 patient |
||
*49 patients had a first-line chemotherapy treatment with docetaxel only, and 21 patients were given both docetaxel and cabazitaxel.
+ Receptor activator of nuclear factor kappa-B ligand.
! Out of 35 patients who have a regular intake of opioids